OSI PHARMACEUTICALS, INC. CONSULTING AND CONFIDENTIAL DISCLOSURE AGREEMENTConsulting Agreement • February 28th, 2008 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
This Consulting and Confidential Disclosure Agreement (“Agreement”) is effective as of the date of the last party to sign below (“Effective Date”) by and between OSI Pharmaceuticals, Inc., a Delaware corporation (together with its affiliates and subsidiaries, “OSI”), having executive offices at 41 Pinelawn Road, Melville, New York 11747, and H.M. (Bob) Pinedo, M.D., Ph.D., an individual (“Consultant”).
OSI PHARMACEUTICALS, INC. CONSULTING AND CONFIDENTIAL DISCLOSURE AGREEMENTConsulting Agreement • February 28th, 2008 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
This Consulting and Confidential Disclosure Agreement (“Agreement”) is effective as of the 23rd day of August, 2007 (“Effective Date”) by and between OSI Pharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “OSI”), having executive offices at 41 Pinelawn Road, Melville, New York 11747, and Walter M. Lovenberg, Ph.D., an individual (“Consultant”).
Dr Daryl Granner Vanderbilt University Medical Centre 707 Light Hall Nashville Tennessee 37232 USA 1st January 2008 Dear Sirs Scientific Advisory Board and Consulting Agreement, dated as of 10th February 2006 between Prosidion Limited and Dr Daryl...Scientific Advisory Board and Consulting Agreement • February 28th, 2008 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This letter will serve as notice of our desire to renew the term of the Agreement for an additional twelve-month period, from 1st January 2008 through to 31st December 2008. All other terms and conditions of the Agreement will remain in full force and effect.
ADDENDUM TO EMPLOYMENT OFFER FOR LINDA E. AMPER CHANGE OF CONTROL AGREEMENTChange of Control Agreement • February 28th, 2008 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This Change of Control Agreement, dated December 4, 2007, between OSI Pharmaceuticals, Inc. (“OSI”) and Linda E. Amper, Ph.D., provides as follows:
